Effect of cognitive reserve on age-related changes in cerebrospinal fluid biomarkers of Alzheimer disease

JAMA Neurology

Volumn 72, Issue 6, 2015, Pages 699-706

  Almeida, Rodrigo P ^a,b,c   Schultz, Stephanie A ^b,c   Austin, Benjamin P ^b,c   Boots, Elizabeth A ^b,c   Dowling, N Maritza ^c   Gleason, Carey E ^b,c   Bendlin, Barbara B ^b,c   Sager, Mark A ^c   Hermann, Bruce P ^c   Zetterberg, Henrik ^d,e   Carlsson, Cynthia M ^b,c   Johnson, Sterling C ^b,c   Asthana, Sanjay ^b,c   Okonkwo, Ozioma C ^b,c  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGE DISTRIBUTION; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; COGNITIVE DEFECT; COGNITIVE RESERVE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE REGISTRY; EDUCATIONAL STATUS; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOASSAY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; AGE; AGED; CEREBROSPINAL FLUID; CROSS-SECTIONAL STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGISTER; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BIOMARKERS; COGNITIVE RESERVE; CROSS-SECTIONAL STUDIES; EDUCATIONAL STATUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; REGISTRIES; TAU PROTEINS;

EID: 84931037352     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.0098     Document Type: Article

References (43)

1. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-357.
2. Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995;273(17):1354-1359.
3. Okonkwo OC, Schultz SA, Oh JM, et al. Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology. 2014;83(19):1753-1760.
4. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012;11(11):1006-1012.
5. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403-413.
6. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349.
7. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965.
8. Okonkwo OC, Mielke MM, Griffith HR, et al; Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Arch Neurol. 2011;68(1):113-119.
9. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010;74(19):1531-1537.
10. Albert MS, De Kosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging. Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
11. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging. Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
12. Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11.labeled Pittsburgh Compound B uptake. Arch Neurol. 2008;65(11):1467-1471.
13. Kemppainen NM, Aalto S, Karrasch M, et al. Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol. 2008;63(1):112-118.
14. Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71(10):1282-1289.
15. Jack CR Jr, Wiste HJ, Weigand SD, et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014;13(10):997-1005.
16. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11(12):1048-1056.
17. Schupf N, Tang MX, Fukuyama H, et al. Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A. 2008;105(37):14052-14057.
18. Mayeux R, Honig LS, Tang MX, et al. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology. 2003;61(9):1185-1190.
19. Assini A, Cammarata S, Vitali A, et al. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology. 2004;63(5):828-831.
20. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid β.peptide in the brain and cognitive decline. JAMA. 2000;283(12):1571-1577.
21. Tabachnick BG, Fidell LS. Using Multivariate Statistics. 5th ed. New York, NY: Harper Collins; 2007.
22. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010;67(3):353-364.
23. Ryan JJ, Paolo AM. A screening procedure for estimating premorbid intelligence in the elderly. Clin Neuropsychol. 1992;6:53-62.
24. Yaffe K, Weston A, Graff-Radford NR, et al. Association of plasma β-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011;305(3):261-266.
25. Mortamais M, Portet F, Brickman AM, et al. Education modulates the impact of white matter lesions on the risk of mild cognitive impairment and dementia. Am J Geriatr Psychiatry. 2014;22(11):1336-1345.
26. Perneczky R, Wagenpfeil S, Lunetta KL, et al. Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study. J Alzheimers Dis. 2009;17(4):855-862.
27. Garibotto V, Borroni B, Kalbe E, et al. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology. 2008;71(17):1342-1349.
28. Perneczky R, Drzezga A, Diehl-Schmid J, et al. Schooling mediates brain reserve in Alzheimer's disease: findings of fluoro-deoxy-glucose.positron emission tomography. J Neurol Neurosurg Psychiatry. 2006;77(9):1060-1063.
29. Ewers M, Insel PS, Stern Y, Weiner MW; Alzheimer's Disease Neuroimaging Initiative (ADNI). Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology. 2013;80(13):1194-1201.
30. Stern Y, Alexander GE, Prohovnik I, Mayeux R. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease. Ann Neurol. 1992;32(3):371-375.
31. Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Zetterberg H, Wallin A. Cognitive reserve in relation to aβ42 in patients converting from MCI to dementia: a follow-up report. Dement Geriatr Cogn Disord. 2009;28(2):110-115.
32. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.
33. Soldan A, Pettigrew C, Li S, et al; BIOCARD Research Team. Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease. Neurobiol Aging. 2013;34(12):2827-2834.
34. Roe CM, Fagan AM, Grant EA, et al. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. Arch Neurol. 2011;68(9):1145-1151.
35. Wang HX, Gustafson DR, Kivipelto M, et al. Education halves the risk of dementia due to apolipoprotein Δ4 allele: a collaborative study from the Swedish Brain Power initiative. Neurobiol Aging. 2012;33(5):1007.e1-1007.e7.
36. Rovio S, Kareholt I, Helkala EL, et al. Leisure-time physical activity atmidlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005;4(11):705-711.
37. Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation. 1993;88(4, pt 1):1973-1998.
38. Liu K, Cedres LB, Stamler J, et al. Relationship of education to major risk factors and death from coronary heart disease, cardiovascular diseases and all causes: findings of three Chicago epidemiologic studies. Circulation. 1982;66(6):1308-1314.
39. Wong MD, Shapiro MF, Boscardin WJ, Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med. 2002;347(20):1585-1592.
40. Gorelick PB, Scuteri A, Black SE, et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-2713.
41. McDowell I, Xi G, Lindsay J, Tierney M. Mapping the connections between education and dementia. J Clin Exp Neuropsychol. 2007;29(2):127-141.
42. Ngandu T, Von Strauss E, Helkala EL, et al. Education and dementia: what lies behind the association? Neurology. 2007;69(14):1442-1450.
43. Khachaturian ZS, Petersen RC, Snyder PJ, et al. Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimers Dement. 2011;7(2):127-132.